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Abstract
In this study we report on a microfluidic device and droplet formation regime capable of
generating clinical-scale quantities of droplet emulsions suitable in size and functionality for in
vivo therapeutics. By increasing the capillary number – based on the flow rate of the continuous
outer phase – in our flow-focusing device, we examine three modes of droplet breakup: geometry-
controlled, dripping, and jetting. Operation of our device in the dripping regime results in the
generation of highly monodisperse liquid perfluoropentane droplets in the appropriate 3–6 µm
range at rates exceeding 105 droplets per second. Based on experimental results relating droplet
diameter and the ratio of the continuous and dispersed phase flow rates, we derive a power series
equation, valid in the dripping regime, to predict droplet size by Dd ≅ 27(QC/QD)−5/12. The
volatile droplets in this study are stable for weeks at room temperature yet undergo rapid liquid-to-
gas phase transition, and volume expansion, above a uniform thermal activation threshold. The
opportunity exists to potentiate locoregional cancer therapies such as thermal ablation and
percutaneous ethanol injection using thermal or acoustic vaporization of these monodisperse
phase-change droplets to intentionally occlude the vessels of a cancer.
INTRODUCTION
Embolization has emerged as an accepted modality for the treatment of various cancers,
including hepatocellular carcinomas, hepatic metastases, and renal cell carcinomas.1 The
intentional occlusion of a vessel, embolization enables the reduction of blood flow into or
out of that vessel, and has typically been used in cancer therapies to produce local ischemia
resulting in tumor necrosis. Established methods of embolization include the placement of a
metal coil or soluble gelatin sponge within the target blood vessel, or the injection of
chemical or particulate agents such as ethanol or polyvinyl alcohol particles to reduce blood
flow at the site of injection or immediately downstream.1,2
Recently the field of medical ultrasound has shown much interest in gas embolotherapy, in
which acoustic or thermal energy induces a droplet emulsion with a volatile liquid core to
undergo a liquid-to-gas phase transition, and volume expansion, to strategically form gas
*Corresponding Author, aplee@uci.edu, Address: 3406 Engineering Hall, University of California, Irvine, Irvine, CA 92697, Phone:
(949) 824-9691, Fax: (949) 824-1727.
NIH Public Access
Author Manuscript
Lab Chip. Author manuscript; available in PMC 2013 April 28.
Published in final edited form as:













emboli in vivo, as shown in Figure 1. Acoustic droplet vaporization (ADV) specifically
refers to the use of focused ultrasound to induce such a transition, in which the applied
acoustic pressure supplies the necessary energy to induce superheated droplet emulsions to
vaporize into microbubbles. The phase-change typically results in microbubbles five to six
times larger in diameter than the original droplets, enabling these gas bubbles to occlude
vessels of sufficiently small diameters, such as capillaries and some arterioles.3,4
Studies thus far have investigated the usefulness of ADV agents to enhance contrast in
ultrasound imaging5, to deliver therapeutics6–8, for enhanced thermal delivery alongside
high-intensity focused ultrasound (HIFU)9, and for occlusion in animal models10. The
choice of liquid core consists of a number of perfluorocarbons, including
perfluoropentane3,7,8,10–15, perfluorohexane8,14, perfluorooctane16, and perfluorobutane.17
Encapsulation of the liquid core inside a lipid, albumin, or polymer shell reduces
coalescence among the droplet population and increases the Laplace pressure sufficiently to
enable these volatile emulsions to remain as superheated droplets at body temperature.3,14
Current methods to generate these phase-change droplets – which include sonication and
high-speed mechanical agitation – typically result in a polydisperse size distribution6,7 and a
non-uniform acoustic activation threshold, as well as in droplets either too large for passage
through the lung capillaries (>6 µm) or too small to occlude the desired vessel (<1 µm).3,10
Thus required are secondary methods of size selection such as filtering5,18 or microfluidic
sorting19 to control the sizes of these distributions. The Antoine equation predicts a negative
logarithmic relationship between vaporization energy and droplet diameter13, meaning that
small droplets require more energy to vaporize than larger droplets due to increased Laplace
pressure. Hence, narrowing the droplet size distribution such that it is highly monodisperse
should result in a uniform response to focused acoustic pressure. As well, a monodisperse
population of ADV agents may better target a specific vessel diameter to improve occlusion
efficiency and efficacy, and would significantly reduce unwanted bioeffects seen in vivo,
including delayed febrile-like reactions and respiratory distress.10,20
Droplet-based microfluidic systems have shown to be effective technologies to produce
droplets21,22 and microbubbles23–25 in the micrometer diameter range with high uniformity.
Yet despite the attractiveness of precision control over size, shape, and composition, these
systems have traditionally been viewed as unviable as bulk manufacturing processes owing
to relatively low generation rates. At present, reporting of clinical-scale generation of
droplet or microbubble emulsions has been limited, and virtually absent for emulsions truly
useful for in vivo intravenous or intra-arterial therapeutics. Most recently Castro-Hernández
et al.26 described a new regime for microbubble generation dependent on the formation of a
strong pressure gradient at the bubble-producing region. Approximately 5 µm in diameter
gas-in-water bubbles were successfully generated at the tip of a long gas ligament with rates
exceeding 105 Hz from a single channel, though bubbles were unstable due to the lack of
significant surfactant or lipid shells. Far less impressive per-channel frequencies have been
observed in liquid-liquid droplet generation systems. Nisisako and Torii27 achieved a
throughput of 320 mL/h in generating approximately 100 µm droplets using a multilayer
device with 256 droplet formation units, a breakup rate of 1.4 × 103 droplets per second per
cross-junction. Kobayashi et al.28 reported the formulation of oil-in-water emulsions at
cumulative rates up to 2.2 × 104 Hz using a total of 1500 submicron-channels on single-
crystal silicon plates, although the emulsions were only moderately monodisperse with a
minimum coefficient of variation (CV) of 9%. In fact, frequency distributions for various
liquid-liquid droplet generation systems, whether water-in-oil or oil-in-water, rarely exceed
several thousand droplets per second from a single channel in forming droplets seldom
smaller than 10 µm in diameter.29 From a healthcare perspective, one could comment that
there is no practical use for these aforementioned emulsions due either to insufficient
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quantity or inappropriate characteristics of the emulsion. Thus, a need in microfluidics still
exists for systems capable of generating clinical-scale amounts of droplet or microbubble
emulsions with suitable size and functionality for therapeutics.
To overcome the limitations of past droplet generation systems, we considered the basic
mechanisms of droplet generation with the intent to find a possible route to produce, in
mass, micrometer-scale droplets with engineered biology. Recent publications on the
physics of fluids have reported the observation of a number of distinct droplet formation
modes in flow-focusing microfluidic devices.30,31 Under controlled experimental conditions,
such a device transitions from geometry-controlled mode to dripping to jetting, affecting the
size and generation frequency by up to an order of magnitude. In particular, Anna et al.30
allude to the dripping mode of droplet breakup as a method to yield droplets smaller than the
minimum device feature size with a shorter primary breakup period than other modes, as yet
demonstrated in the literature with a healthcare intent. We thus set out to use the dripping
regime to meet our objective of the clinic-ready manufacture of liquid perfluoropentane
droplets as phase-change agents for cancer treatment.
In this work we present a microfluidic device, operated in the dripping regime, for the super
high-speed generation (>105 Hz) of monodisperse liquid perfluoropentane droplets in the
desired size range for gas embolotherapy. Resulting droplet populations exhibit
polydispersity index values of <5%, are stable at room temperature for several weeks, and
are thermally vaporized at 88°C in a water bath. These liquid perfluoropentane droplets thus
exhibit phase-change and are ideal for targeted vessel occlusion alongside such cancer
therapies as HIFU, radiofrequency ablation (RFA), laser ablation (LA), laser-induced
thermotherapy (LITT), and chemotherapy. Our microfluidic device, shown in Figure 2,
features a hydrodynamic flow-focusing region and expanding nozzle geometry to generate
monodisperse liquid perfluoropentane droplets encapsulated in a lipid shell.
MATERIALS AND METHODS
Device Design
The microfluidic device, made of polydimethylsiloxane (PDMS) on a glass substrate,
consists of fixed geometric channels designed to direct liquid perfluoropentane and a lipid
solution to an orifice 7 µm in width. Filter channels of the same dimension immediately
follow both inlets to prevent clogging at the orifice. Serpentine distribution channels
increase the resistance between inlets and the orifice chamber, minimizing the susceptibility
of droplet generation to disruptions in the fluid flows and increasing the pressure drop along
the longitudinal axis of the device. Liquid perfluoropentane and lipid distribution channels
each measure 38 µm in width. The post-orifice channel measures 30 µm in width.
Device Operation: Droplet Formation Regimes
The principle behind a microfluidic flow-focusing system is to force a central stream of a
dispersed phase and two side sheath flows of a continuous phase through a small orifice,
causing a focusing effect and a breaking of the thread at the orifice into uniform
emulsions.32
Most traditional flow-focusing devices have been operated in the geometry-controlled mode,
termed for the large dependence of droplet size on the smallest feature size in the device –
the orifice. In this mode droplets break off from the dispersed phase finger following a
protrude-and-retract mechanism.33 Droplets in the geometry-controlled mode are highly
monodisperse but limited in minimum size by the width of the orifice.
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An increase in the capillary number Ca = ηV/γEQ, where η is the viscosity and V is the
superficial velocity of the continuous outer phase, and γEQ is the equilibrium surface tension
between the two fluid phases, leads to droplet generation in the dripping regime.30 This
regime produces monodisperse droplets smaller than the size of the orifice due to a
narrowing of the dispersed phase finger. The dripping mode is characterized by a dispersed
phase tip that does not retract but rather remains at a fixed location in the orifice, generating
a stream of droplets off the tip due to Rayleigh capillary instability.
A further increase in the capillary number leads to droplet generation in the jetting mode,
wherein the dispersed phase finger extends far into the post-orifice channel. Droplets, which
break off the tip of the dispersed phase finger due again to Rayleigh capillary instability,
tend to be as large or larger than the orifice width in the jetting mode and may be
polydisperse.30
By adjusting the flow parameters and continuous phase viscosity, we thus aimed to operate
our flow-focusing microfluidic device in the dripping regime to attain droplets of the desired
size for gas embolotherapy (1–6 µm in diameter).
Microfabrication and Assembly
Standard soft lithography techniques34 were used to fabricate the microfluidic devices.
Devices were designed as vector-based fluidic channel geometries in Illustrator (Adobe) and
printed at 20,000 DPI by CAD/Art Services. In a class 10,000 clean room, a 25 µm layer of
UV-curable epoxy (SU8-25, MicroChem) was spun onto a 3-inch silicon wafer and exposed
to UV-light through the photomask and developed.
Next, PDMS (Sylguard 184, Dow Corning), consisting of 10:1 prepolymer to curing agent,
was poured over the patterned silicon wafer in a Petri dish to mold a silicon elastomer
replica. The Petri dish was then vacuumed for at least half an hour to degas the PDMS and
left overnight in a 70°C temperature-controlled dry oven to cure fully. The device was
peeled from the hard master in a laminar flow chamber and inlets and outlet were punched
using a blunt 18G needle. A soda lime glass slide was cleaned with isopropyl alcohol prior
to use as the substrate. The cured PDMS device and clean glass slide were bonded after 150
seconds in air plasma at 250 millitorr. DI water was added to the outlet after plasma
preparation and allowed to wick in order to maintain the hydrophilicity of the channels.
Chemicals
A lipid shell was chosen over an albumin shell, as albumin shells have shown an increased
tendency to become lodged in the pulmonary capillaries.10 Adapted from Hettiarachchi et
al.35, the lipid flow stream consists of an aqueous glycerol mixture with the stabilizing lipids
DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine, Avanti Polar Lipids) and DSPE-
PEG2000 (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene
glycol)-2000], Avanti Polar Lipids). Briefly, 5 mg DSPC and 1.96 mg DSPE-PEG2000 were
combined in a glass vial and dissolved in chloroform (CHCl3, Sigma) to form a
homogeneous mixture. The solvent was evaporated with a nitrogen stream and the vial was
placed in a vacuum chamber for a half hour to ensure a complete dry. Five mL of ultra-pure
water was added to the dry lipid mixture and sonicated at room temperature for 20 minutes.
The solution was combined with an additional 1 mL of ultra-pure water, 4 mL of glycerol
(Sigma), and 1 mL of nonionic surfactant (Pluronic F-68, Sigma), sonicated at room
temperature for 10 minutes, and stirred overnight to ensure air saturation. The lipid solution
was sonicated again for 15 minutes immediately prior to use to minimize unwanted
liposome formation.
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Perfluoropentane (dodecafluoropentane, C5F12, FluoroMed) was chosen as the liquid
perfluorocarbon. Typical physical characteristics of perfluoropentane include a boiling point
of 29°C – below body temperature, 37°C – and a molecular weight of 288 g/g-mole.
Imaging and Characterization
The microfluidic device was mounted on an inverted microscope (IX71, Olympus) and
external fluidic connections were made. The continuous lipid phase was supplied to the
device via flexible tubing (Tygon, Sigma) and pumped at a volumetric flow rate of QL using
a digitally controlled syringe pump (Pico Plus, Harvard Apparatus). The dispersed liquid
perfluoropentane phase was delivered into the inlet of the microfluidic chamber using a
homemade pressure pumping system controlled by an analytic regulator. Pressure pumping
of the dispersed phase effectively minimized fluctuations in the liquid perfluoropentane flow
and eliminated the buildup of pressure, characteristic of constant flow rate mechanical
pumping, in the inner phase channels. As well, loading the liquid perfluoropentane was
made easier by the homemade pressure pump as the low kinematic viscosity of this
perfluorocarbon at room temperature (0.4 cSt) tends to complicate the loading of the syringe
for mechanical pumping. The volumetric flow rate (µL/min) of the dispersed liquid
perfluoropentane phase was determined from the droplet diameter D and the droplet
generation frequency fd as QP = (πD3/6) fd*C, where C represents the necessary conversion
factors. The 30-PSI limit of the analytical regulator prevented the use of pressure pumping
for the continuous lipid phase.
A high-speed camera (V310 Phantom, Vision Research) was used to record videos of the
droplet generation. The image analysis program ImageJ (NIH) was used for data processing
and measurements. Production rates (droplets per second) were calculated from the videos
by counting the number of droplets per 500 frames and multiplying by the frame rate.
Droplet diameters were back calculated from area measurements of at least 50 droplets taken
optically from recorded images using ImageJ. The polydispersity index σ = δ/D*100% for
each flow condition was calculated from the average droplet diameter D and standard
deviation δ.
Droplet Stability
Droplets were collected in the outlet well of the microfluidic device and transferred to a
sealed 7 mL glass vial. In contrast to previous reports, which stored droplets at 4–5°C10,15,
droplets in this study were stored at room temperature to assess the viability of the droplets
in an on-the-shelf setting. At Days 0 and 14, 300 µL aliquots of droplet solution were
pipetted onto glass slides for stability studies. ImageJ was used to analyze at least 1000
droplets, imaged in population at 40× magnification, to establish average diameter and
monodispersity over the two-week period.
Vaporization of Droplets in a Water Bath
To determine the vaporization temperature of the perfluoropentane droplets, 300 µL aliquots
of droplet solution were added to 2 mL of dilute lipid solution in a 7 mL vented glass vial.
The elevated density of liquid perfluoropentane (1.66 g/mL) relative to the solution meant
that the droplets rested at the base of the vial. The vial was suspended in a stirred water bath
and the bath temperature was gradually raised until we observed gas bubble formation and
thus phase transition. The experiment was conducted twice again with pure liquid
perfluoropentane and pure lipid solution as controls against unintended microbubble
formation.
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Channel geometry, in addition to the compositions of fluid layers and the presence of
surfactants, affects the stability of droplets post-production in the microfluidic device.
Geometric optimization of the flow-focusing region enabled droplets to be produced in a
single file, even at rates exceeding 105 Hz. To increase the distance between generated
droplets at higher lipid and liquid perfluoropentane flow rates, the expanding nozzle and
post-orifice channels were narrowed to widths of 70 µm and 30 µm. This narrowing
minimized contact inhibitions in the high-flow velocity environment of the expansion
chamber, where shell resistances are low, preventing droplet fusion before collection in the
outlet well.
Droplet Formation Regimes
By adjusting the flow parameters in our flow-focusing device, we observed each of the three
distinct droplet formation regimes detailed. At low continuous phase flow rates QL, and
correspondingly low dispersed phase pressures PP, our device produced droplets in the
geometry-controlled mode. As shown in Figure 3a – comprising a series of overlaid images,
successive in time – the dispersed phase finger, initially upstream of the orifice in this mode,
protrudes beyond the constriction of the orifice and experiences a pinching from the
sidewalls, causing droplets to shear off. This protrude-and-retract mechanism limits the
droplet diameter to the width of the orifice. Droplets generated in the geometry-controlled
mode ranged in diameter from 7.9 ± .1 µm at 2.44×104 Hz to 10.8 ± .2 µm at 3.28×104 Hz.
Increasing the continuous phase flow (and, correspondingly, the capillary number) causes an
abrupt transition to the dripping regime of droplet formation, characterized by a dispersed
phase finger that narrows to a fine tip and remains in the orifice (Figure 3b). Droplets, which
break off the tip at high frequency due to “steady” Rayleigh capillary instability, vary in size
according to the width of the dispersed phase finger rather than that of the orifice. Diameters
of droplets generated in the dripping regime ranged from 3.6 ± .2 µm at 1.36×105 Hz to 10.8
± .1 µm at 5.00×104 Hz.
High continuous phase flows paired with correspondingly high dispersed phase pressures
transitioned droplet formation into the jetting mode. Figure 3c overlays a series of images,
successive in time, to demonstrate the break off of droplets in this mode due to “dynamic”
Rayleigh capillary instability; relative to in the dripping regime, the dispersed phase tip
extends far beyond the orifice and fluctuates in both length and width. Droplets at the
transition to the jetting regime ranged in diameter from 9.3 ± .2 µm at 7.68×104 Hz to 13.5
± .1 µm at 3.84×104 Hz.
Generation of Liquid Perfluoropentane Droplets
The flow rate parameters are determinants for stable production and precise control over the
size and generation frequency of the liquid perfluoropentane droplets. In general and
regardless of the droplet formation regime, droplet diameter D – and consequently volume V
– increases with the dispersed phase pressure PP for a fixed continuous phase flow QL,
consistent with previous studies.23,26,35 Shown in Figure 4a, the width of the orifice limits
the minimum droplet size in the geometry-controlled mode, while much smaller droplets can
be generated in the dripping regime. The minimum droplet diameter tends to decrease with
increasing QL, and thus increasing capillary number, as the smallest droplets observed in
this study occurred at the highest continuous flow rates.
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An interesting observation emerged when establishing trends in the droplet generation
frequency fd (Figure 4b). In geometry-controlled mode, fd tends to increase with PP for a
fixed QL in order to conserve mass. Conversely, for a given QL in the dripping regime,
decreasing PP significantly quickens the generation frequency (increases fd) while reducing
D, hence achieving the desired super high-speed generation of functional droplets suitable
for therapeutic applications. Overall and as expected, fd tends to increase with QL.
The sequence of high-speed images in Figure 5 illustrates the general trends observed in the
dripping regime. In particular as droplets become small, the width of the dispersed phase
finger heavily influences the diameter of the droplet after it breaks off from the tip.
Shown in Figure 6 are droplet generation frequencies obtained from high-speed videos of
production and corresponding polydispersity indexes, plotted as a function of droplet
diameter. When operated in the dripping regime our device clearly produces liquid
perfluoropentane droplets in the desired 3–6 µm range with high monodispersity at rates
equal to or exceeding 105 Hz. Whereas no general trend appears to connect droplet diameter
and generation frequency in geometry-controlled mode, D tends to decrease as fd quickens
in the dripping regime. Simple adjustment of the flow parameters enabled the generation of
droplets spanning a wide range of diameters, with a polydispersity index less than 5% for
each condition.
Determining the liquid perfluoropentane volumetric flow rate QP as detailed, we evaluated
the influence of the dimensionless flow rate ratio φ = QL/QP on droplet diameter and
generation frequency. Shown in Figure 7a, a key relationship emerges in the dripping regime
relating D and φ to predict droplet diameter based solely on the dimensionless flow rate ratio
as D = 27.445φ−.414 (r2 = .99). Rounding, we characterize our flow-focusing droplet
generator, operated in the dripping regime, in generic terms by
(1)
where Dd represents the droplet diameter, and QC and QD represent the continuous and
dispersed phase flow rates. Note that the exponent 5/12 matches the exponent reported in
Castro-Hernández et al.26 to calculate gas bubble diameter based on the ratio of the flows in
a high-speed regime.
The droplet generation frequency shows relatively less dependence on the dimensionless
flow rate ratio (Figure 7b). In general, however, fd increases with φ in the dripping regime
and decreases with φ in geometry-controlled mode. As in Anna et al.30, transitions between
the droplet formation regimes are weakly dependent on φ; rather, capillary number plays a
more determining role in controlling the mode of droplet breakup.
This study used low lipid flow rates (12–26 µL/min) and correspondingly low liquid
perfluoropentane pressures in order to conserve fluids and better demonstrate the viability of
high-speed droplet generation as a bulk manufacturing process. By comparison,
Hettiarachchi et al.23 supplied the lipid phase at rates between 30–120 µL/min. Based on the
trends observed in Figures 4b and 7b, even quicker droplet generation frequencies may be
attained by increasing the continuous phase flow to further push the capillary number. As
well, multiplexing numerous flow-focusing circuits to expand the number of droplet
formation units, while maintaining device operation in the dripping regime, would scale the
throughput. A 10× scale-up, for instance, would reduce the time to produce 1 × 109 droplets
– similar in scale to the amount of droplets formed by mechanical agitation, and well beyond
the estimated 2 × 107 monodisperse emulsions35 necessary for therapeutics in humans –
from several hours to mere minutes.
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We assessed a population of droplets with a mean diameter of 4.5 µm for size stability over
a two-week time span. To our knowledge this study is the first to simulate an on-the-shelf
environment by storing phase-change droplets at room temperature. Over two weeks the
mean droplet diameter drifted less than 4%, from 4.5 ± .2 µm to 4.3 ± .3 µm (Figure 8). It
may be possible to prolong the shelf life beyond several weeks by modifying the poloxamer
or PEG group, though unnecessary in practice considering that clinical phase-change and
contrast agents formed via mechanical agitation are injected immediately into the patient.
Thermal Vaporization
The relatively low boiling point of liquid perfluoropentane (29°C) suggests spontaneous
liquid-to-gas transition at body temperature; however, consistent with previous studies3,14,
encapsulation of the perfluorocarbon in a lipid shell increases the Laplace pressure
sufficiently to stabilize the droplets well beyond the natural boiling point of pure liquid
perfluoropentane. We observed rapid thermal vaporization of multiple droplet populations,
collected at different days, at 88°C in a stirred water bath. Droplets remain in a superheated
state prior to this activation threshold.
Shown in Figure 9, gas bubbles formed by vaporization expanded well beyond the volume
predicted by the ideal gas law, PV = nRT, which approximates a volume expansion factor of
1253. Upon activation, 4.5 ± .2 µm droplets initially converted into gas bubbles 106.7 ± 4.6
µm in diameter, a diameter expansion of 24x. Kripfgans et al.3 detailed this further
expansion as due to the intake of dissolved gases from the host fluid after conversion of the
droplet to the gas bubble of pure perfluoropentane, an effect we have observed
experimentally in our previous studies with perfluorocarbons.17 That the carrier fluid was
not degassed prior to heating contributed to this large initial increase in size. Subsequent
dissolution of these extra gases resulted in gas bubbles with a resting diameter of 27.4 ± 1.2
µm, a 6x increase from the original droplet diameter, imaged several days after vaporization
(Figure 9, inset).
These experiments were repeated for vials containing pure liquid perfluoropentane and pure
lipid solution. Under observation, pure liquid perfluoropentane transitioned directly to gas
perfluoropentane, thus leaving an “empty” vial. Pure lipid solution boiled up to 120°C
without the formation of gas bubbles.
The size stability of our droplets enabled consistent thermal activation of droplet populations
stored at room temperature over two weeks. At threshold, droplet activation occurs in a near
simultaneous manner. Likewise, we demonstrate in a parallel study that monodisperse
droplets generated by our microfluidic device respond uniformly to acoustic pressure
delivered from a 5 MHz piston transducer.36 This parallel study confirms our initial
hypothesis that acoustic droplet vaporization can be made homogenous by the precision
engineering of phase-change agents using microfluidics.
Consistent thermal and acoustic responses make these liquid perfluoropentane droplets ideal
for targeted vessel occlusion to enhance HIFU, RFA, LA, and LITT in the treatment of
cancers such as hepatocellular carcinomas, hepatic metastases, and renal cell carcinomas.
The inclusion of an anti-cancer drug layer within the droplet may further potentiate these
treatment modalities. Our device design lends itself to the inclusion of such a drug layer by
combining a second hydrodynamic flow-focusing region at the droplet formation unit, as
done in microbubble studies by Hettiarachchi et al.35 Chemoembolization – the addition of a
chemotherapeutic agent – has been used to reduce perfusion and deliver therapeutics to treat
renal cell carcinoma alongside RFA37 and hepatocellular carcinoma alongside RFA38 and
HIFU39. Besides forming polydisperse size distributions, conventional production
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techniques result in inconsistent drug dosages. Manufacturing utilizing microfluidics enables
the accurate control of therapeutic payloads35, and thus may improve localized drug delivery
as well as thermal and acoustic responses. Further, adaptation of our microfluidic device to
produce monodisperse double emulsions may enable the encapsulation of hydrophilic drugs
such as thrombin8 to extend the duration of occlusions generated by phase-change agents.
CONCLUSION
With microfluidics we can generate highly monodisperse phase-change droplets in the size
range suitable for gas embolotherapy as a cancer treatment. By adjusting the flow rate of the
continuous outer phase, we varied the capillary number and observed three distinct droplet
formation regimes: traditional geometry-controlled mode, characterized by a protrude-and-
retract mechanism of droplet break off; dripping, characterized by “steady” Rayleigh
capillary instability; and jetting, characterized by “dynamic” Rayleigh capillary instability.
Geometric optimization of the flow-focusing region and operation of the device in the
dripping regime enabled the single-file generation of droplets at rates exceeding 105 Hz. To
our knowledge this study is the first to report on the generation of clinical-scale quantities of
droplet emulsions truly suitable for in vivo intravenous therapeutics.
For our flow-focusing device operated in the dripping regime, we can predict droplet
diameter Dd based on the dimensionless ratio of the flow rates of the continuous outer phase
QC and the dispersed inner phase QD. In simplified terms, we characterize our device in the
dripping regime by Dd ≅ 27(QC/QD)−5/12.
Droplet populations generated by our microfluidic device are monodisperse, stable at room
temperature, and transition uniformly to gas bubbles when presented with thermal and
acoustic stimuli. Looking ahead, we aim to build a drug layer into our liquid
perfluoropentane droplets to generate, using super high-speed microfluidics, phase-change
droplets for gas chemoembolotherapy. Simultaneous delivery of a chemotherapeutic agent
should elevate local concentrations of the drug with little escape to the systemic circulation
due to vessel occlusion. Combining gas chemoembolotherapy with locoregional therapies
such as thermal ablation and percutaneous ethanol injection presents a nice prospect to
enhance heat and alcohol trapping and more effectively treat cancers.
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Schematic of the liquid-to-gas phase transition of a phase-change droplet. When presented
with acoustic or thermal stimuli of a threshold amount, the volatile liquid core of the droplet
rapidly vaporizes within the lipid shell. Expansion to a gas bubble enables the intentional
occlusion of a target vessel in vivo. Other possible stimuli include light and mechanical
pressure.
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Geometry of the device for the generation of liquid perfluoropentane phase-change droplets.
(a) Schematic view of the microfluidic flow-focusing device. All channels are rectangular
with a height of 25 µm. (b) Image of the flow-focusing region. Lipid solution and liquid
perfluoropentane distribution channels measure 38 µm in width and direct flows to a 7 µm
orifice. Expanding nozzle geometry precedes a post-orifice channel 30 µm in width. (c)
Overhead view of assembled PDMS device relative to a dime.
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Representative images of three distinct droplet formation regimes. (a) Geometry-controlled.
A series of overlaid images, successive in time, demonstrate the protrude-and-retract
mechanism of the dispersed phase finger. (b) Dripping. Droplets break off from the tip of the
dispersed phase finger at high rates due to “steady” Rayleigh capillary instability. (c) Jetting.
A series of overlaid images, successive in time, demonstrate the break off of droplets due to
“dynamic” Rayleigh capillary instability. Image height is 25 µm.
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Diagrams of the production characteristics as determined by the flow parameters. Boxes
distinguish geometry-controlled and jetting modes of droplet formation from dripping. (a)
Droplet diameter D as a function of the lipid flow QL and the liquid perfluoropentane
pressure PP. (b) Generation frequency fd as a function of QL and PP.
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Sequence of images showing the effect of liquid perfluoropentane pressure for two lipid
flows in the dripping regime. Droplet diameter decreases and generation frequency quickens
as the dimensionless flow rate ratio φ = QL/QP increases. (a) QL = 18 µL/min. Top to
bottom: PP = 17 PSI, φ = 55, D = 4.9 ± .2 µm, fd = 8.82 × 104 Hz; PP = 18 PSI, φ = 18, D =
8.6 ± .1 µm, fd = 5.04 × 104 Hz; PP = 19 PSI, φ = 9, D = 10.0 ± .2 µm, fd = 4.80 × 104 Hz.
(b) QL = 22 µL/min. Top to bottom: PP = 20 PSI, φ = 128, D = 3.8 ± .2 µm, fd = 1.00 × 105
Hz; PP = 21 PSI, φ = 20, D = 7.9 ± .1 µm, fd = 7.00 × 104 Hz; PP = 22 PSI, φ = 12, D = 9.8
± .2 µm, fd = 6.12 × 104 Hz. Image height is 25 µm.
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Plots relating generation frequency and polydispersity index to droplet size. The dripping
regime enables droplet formation in the appropriate 3–6 µm range at high frequency and
monodispersity. (a) Generation frequency fd as a function of droplet diameter D. (b)
Polydispersity index (PDI) as a function of D. All flow conditions generated droplets with
PDI < 5%.
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Diagrams of the production characteristics as determined by the ratio of the continuous lipid
flow to the dispersed liquid perfluoropentane flow, φ = QL/QP. (a) Droplet diameter D as a
function φ. For a given φ, droplet formation in geometry-controlled mode generates droplets
of a larger size than in dripping. A power-series equation, valid in the dripping regime,
emerges to predict droplet size based on the dimensionless flow rate ratio as D =
27.445φ−.414 (r2 = .99). (b) Generation frequency fd as a function of φ. Increasing φ tends to
slow fd in geometry-controlled mode and quicken fd in dripping.
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Images showing stability of a droplet population over a two-week time period. Droplets 4.5
µm in diameter drifted less than 4% in size over 14 days in a sealed glass vial at room
temperature. Thus our phase-change droplets exhibited high stability in a true on-the-shelf
setting. Scale bar represents 5 µm.
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Thermal vaporization of a population of liquid perfluoropentane droplets after heating in a
stirred water bath. Rapid droplet activation was observed at a water bath temperature of
88°C. Upon vaporization, 4.5 µm droplets initially transitioned into gas bubbles 106.7 µm in
diameter. (inset) Occlusive bubbles with a resting diameter of 27.4 µm resulted following
dissolution of extra gases.
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